1
Nagashima Shinya, Nagata Hiroshi, Iwata Masahiro, Yokota Masaki, Moritomo Hiroyuki, Nakai Eiichi, Kuromitsu Sadao, Ohga Keiko, Takeuchi Makoto: (Ja) ジアミノピリミジンカルボキサミド誘導体, (En) Diaminopyrimidinecarboxa mide derivative. Yamanouchi Pharmaceutical, Nagashima Shinya, Nagata Hiroshi, Iwata Masahiro, Yokota Masaki, Moritomo Hiroyuki, Nakai Eiichi, Kuromitsu Sadao, Ohga Keiko, Takeuchi Makoto, NAGAI Shozo, January 8, 2004: WO/2004/002964 (69 worldwide citation)

(EN) A compound which is usable in the prevention of and/or treatments for respiratory diseases in which STAT 6 participates, especially asthma, chronic obstructive pulmonary diseases, etc. The compound is either a pyrimidine derivative having in the 2-position an arylamino or arylethylamino group o ...


2
Nagashima Shinya: Optical wavemeter. Ando Electric, January 25, 1995: GB2280261-A (23 worldwide citation)

In an optical wavemeter light 26 of unknown wavelength is divided into first and second beams by a beam splitter. The first beam is reflected by a fixed mirror 21 back into the beam splitter, and is then received by a light receiver 24. The second beam is reflected by a moving mirror 22 back into th ...


3
Nagashima Shinya, Hondo Takeshi, Osada Hiroshi, Ogiyama Takashi, Hoshii Hiroaki, Konya Toru, Oga Keiko, Kuromitsu Sadao: Pyrroloprymidine derivative or its salt. Astellas Pharma, September 14, 2006: JP2006-241089 (11 worldwide citation)

PROBLEM TO BE SOLVED: To provide a compound which can be used for preventing and treating respiratory diseases related to STAT6, especially asthma, chronic obstructive pulmonary diseases, and the like.SOLUTION: This pyrroloprymidine derivative represented by general formula (I) [A: =CH-, =N-, or the ...


4
Nagashima Shinya, Nagata Hiroshi, Iwata Masahiro, Yokota Masaki, Moritomo Hiroyuki, Nakai Eiichi, Kuromitsu Sadao, Ohga Keiko, Takeuchi Makoto: Derive de diaminopyrimidinecarboxamide, Diaminopyrimidinecarboxamide derivative. Yamanouchi Pharmaceutical, Astellas Pharma, Dennison Associates, May 24, 2011: CA2490888 (6 worldwide citation)

A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may ...


5
Aoki Shoichi, Nagashima Shinya: Optical fiber chromatic dispersion distribution measuring apparatus and measuring method. Ando Electric, June 5, 2002: EP1211499-A2 (3 worldwide citation)

An apparatus for measuring the chromatic dispersion profile of an optical fiber using two light sources 1 and 2 at least one of which is tunable in wavelength, in which two light beams of different wavelengths from said two light sources are injected into a optical fiber under test 7 and the four-wa ...


6
Nagashima Shinya: Polarization mode dispersion measurement and zero dispersion measurement device. Ando Electric, April 6, 2001: JP2001-091408 (2 worldwide citation)

PROBLEM TO BE SOLVED: To accurately measure a polarization mode dispersion of a long distance fiber and to shorten a measurement time in a polarization mode dispersion measurement and zero dispersion wavelength measurement device. SOLUTION: This polarization mode dispersion measurement and zero disp ...


7
Nagashima Shinya: Vehicular light unit. Ichikoh, January 25, 2007: JP2007-015578 (1 worldwide citation)

PROBLEM TO BE SOLVED: To provide a vehicular light unit suitably detecting the open failure or the short circuit failure of a power source made from a plurality of light-emitting elements connected in a forward direction in series.SOLUTION: The vehicular light unit 1 is installed in a vehicle. The v ...


8
TANAKA AKIRA, MUKOYOSHI KOICHIRO, KUNIKAWA SHIGEKI, TAKASUNA YUJI, MAEDA JUN, CHIDA NOBORU, NAGASHIMA SHINYA: 2,4-DIAMINOPYRIMIDINE COMPOUND, 2,4-DIAMINOPYRIMIDINVERBINDUNG, COMPOSÉ 2,4-DIAMINOPYRIMIDINE. ASTELLAS PHARMA, May 25, 2011: EP2325175-A1 (1 worldwide citation)

[Problem] Provided is a compound which is useful as an active ingredient for a pharmaceutical having a PKC inhibition activity, particularly a pharmaceutical composition for inhibiting acute rejection occurring in transplantation. [Means for Solution] The present inventors have conducted extensive s ...


9
Nagashima Shinya, Kontani Toru, Nagata Hiroshi, Matsushima Yuji, Hamaguchi Hisao, Koshika Tadatsura: (Ja) アザ架橋環化合物, (En) Aza-bridged-ring compound. Astellas Pharma, Nagashima Shinya, Kontani Toru, Nagata Hiroshi, Matsushima Yuji, Hamaguchi Hisao, Koshika Tadatsura, MORITA Hiroshi, August 14, 2008: WO/2008/096870 (1 worldwide citation)

(EN) [PROBLEMS] To provide a compound which has an antagonistic activity on a muscarinic M3 receptor and is therefore useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as chronic obstructive pulmonary disease (COPD) and asthma. [MEANS FOR SOLV ...


10
SHOJI Tetsuya, MANABE Akira, MIYAMOTO Noritaka, HIRAOKA Motoki, OMURA Shinya, ICHIGOZAKI Daisuke, NAGASHIMA Shinya: [ja] 希土類磁石とその製造方法, [fr] AIMANT DE TERRES RARES ET PROCÉDÉ DE PRODUCTION DE CE DERNIER, [en] RARE-EARTH MAGNET AND PROCESS FOR PRODUCING SAME. SHOJI Tetsuya, MANABE Akira, MIYAMOTO Noritaka, HIRAOKA Motoki, OMURA Shinya, ICHIGOZAKI Daisuke, NAGASHIMA Shinya, TOYOTA JIDOSHA KABUSHIKI KAISHA, HIRAKI Yusuke, May 23, 2013: WO/2013/073486 (1 worldwide citation)

[en] Provided is a rare-earth magnet which contains no heavy rare-earth metals such as Dy and Tb in the grain boundary phase and in which a modifying alloy for heightening the coercive force (in particular, high-temperature coercive force) was infiltrated at a lower temperature than in conventional ...